A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection

Last updated: January 3, 2025
Sponsor: Umbria Bioengineering Technologies
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Cancer

Treatment

Clinical investigation medical device class IIa marked CE

Clinical Study ID

NCT05300464
UBT 2022-01
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

This is a multicentric, single arm, prospective, stratified by breast density clinical investigation to confirm the ability of the microwave mammogram 'MammoWave' to detect breast lesions.

MammoWave is a innovative medical device, class IIa marked CE, which uses microwaves instead of ionazing radiation (x-ray) for breast lesions. Specifically MammoWave employs a novel technique wich generates images by processing very low power (<1mW) microwave.

The MammoWave exam takes few minutes for breast and is performed with the patient lying in a confortable facing down position.

MammoWave is safe to be used at any age, in any condition (pregnancy, specific illness and for unlimited number of times.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed Informed consent Form

  • Women

  • Adult ≥ 18 years old

  • Having a radiologist study output obtained using mammography within the last month.Such radiologist study output may be integrated with ultrasound and /or magneticresonance imaging output if deemed necessary by the responsible investigator andwhen available. The radiological output will be integrated with histological one ifdeemed necessary by the responsible investigator and when available.

  • Patients willing to comply with study protocol and recommendations

Exclusion

Exclusion Criteria:

  • Patients who belong to any vulnerable group

  • Patients with implanted electronic devices

  • Patients who have undergone biopsy less than one week before MammoWave scan

  • Patients with nipple piercings (unless they are removed prior to examination)

  • Pregnancy or breastfeeding

Study Design

Total Participants: 600
Treatment Group(s): 1
Primary Treatment: Clinical investigation medical device class IIa marked CE
Phase:
Study Start date:
January 07, 2023
Estimated Completion Date:
January 31, 2027

Study Description

The maximum number of participants to the clinical investigation will be 600 (for all the sites). The study will be composed of two phases: a preliminary phase to 'optimize the imaging algorithm for each apparatus installed at each centre', where 15 volunteers (in each centre) having breast with no lesions (NL) will be examined by MammoWave. In the second phase, the remaining people will be enrolled (BL will be 50% of total) and examined by MammoWave by the clinical investigator, and results will be compared with the effective diagnosis already obtained by standard clinical methods. BL includes malignant lesions (BC) and benign lesions, and may be palpable or non-palpable lesions. BL includes also isolated clustered microcalcifications.

The primary gol of the clinical study is to assess MammoWave's ability in BL detection.

The study will involve investigational sites in Italy, Germany and Spain.

Connect with a study center

  • Brustdiagnostik München

    München, 80331
    Germany

    Site Not Available

  • Ospedale San Giovanni Battista - USL Umbria 2

    Foligno, Perugia 06034
    Italy

    Site Not Available

  • IRCCS Policlinico San Martino

    Genova, 16132
    Italy

    Active - Recruiting

  • Hospital Universitario de Toledo

    Toledo, 45007
    Spain

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.